Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Achieve Life Sciences, Inc. (ACHV : NSDQ)

• Company Description    Achieve Life Sciences Inc. is a pharmaceutical company. It develops and commercializes cytisine treatment to help people battling nicotine addiction. The Company's product candidates include Custirsen, Apatorsen and OGX-225. Achieve Life Sciences Inc., formerly known as OncoGenex Pharmaceuticals Inc., is based in Bothell, United States. Number of Employees: 25

• Price / Volume Information    Yesterday's Closing Price: $2.23 Daily Weekly Monthly 20 Day Moving Average: 987,242 shares Shares Outstanding: 34.69 (millions) Market Capitalization: $77.35 (millions) Beta: 1.63 52 Week High: $5.31 52 Week Low: $1.84 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -37.71% -40.35% 12 Week 2.29% -15.92% Year To Date -36.65% -39.64%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1040 West Georgia Street Suite 1030 - Vancouver,BC V6E 4H1 CAN ph: 604-210-2217 fax: 425-686-1600 ir@achievelifesciences.com http://www.achievelifesciences.com

• General Corporate Information    Officers Richard Stewart - Chief Executive Officer and Director Thomas B. King - Chairman Cindy Jacobs - President Mark Oki - Chief Financial Officer Jerry Wan - Vice President; Finance Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 004468500 SIC: 2835 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/12/25 Share - Related Items Shares Outstanding: 34.69 Most Recent Split Date: 7.00 (0.05:1) Beta: 1.63 Market Capitalization: $77.35 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.37 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.23 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 7.52 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -42.31% vs. Previous Quarter: -2.78% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/25 - -176.11 12/31/24 - -110.62 09/30/24 - -108.30 ROA 03/31/25 - -103.32 12/31/24 - -71.96 09/30/24 - -65.20 Current Ratio 03/31/25 - 3.51 12/31/24 - 5.46 09/30/24 - 6.78 Quick Ratio 03/31/25 - 3.51 12/31/24 - 5.46 09/30/24 - 6.78 Operating Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Net Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Pre-Tax Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Book Value 03/31/25 - 0.30 12/31/24 - 0.61 09/30/24 - 0.91 Inventory Turnover 03/31/25 - - 12/31/24 - - 09/30/24 - - Debt-to-Equity 03/31/25 - 0.85 12/31/24 - 0.47 09/30/24 - 0.31 Debt-to-Capital 03/31/25 - 45.87 12/31/24 - 32.15 09/30/24 - 23.84

Powered by Zacks Investment Research ©